CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
GWP42003 +1 moredrug
Likely dose
GWP42003 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01562314
NCT01562314Phase 2Completed
CompareCT.gov

A Randomised, Double-blind, Placebo-controlled Parallel Group, Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis

GW Research Ltd·interventional·Posted Mar 23, 2012·Updated Aug 9, 2018

In Brief

A Phase 2 clinical trial evaluating GWP42003 and Placebo for Ulcerative Colitis. Completed, enrolled 60 participants across 8 sites.

Detailed Summary

This study was conducted to determine the efficacy and safety of GWP42003 compared with placebo by the percentage of participants achieving remission quantified as a Mayo score of 2 or less (with no sub-score \>1) after 10 weeks of treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 23, 2012
Enrollment StartMay 9, 2012
Primary CompletionAug 5, 2014
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 14.3 years ago

Interventions

GWP42003drug

1 to 5 50 mg capsules taken BID

Placebodrug

1 to 5 matching capsules taken BID